2-hydroxyethyl 4-nitrophenyl carbonate | 252337-28-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-hydroxyethyl 4-nitrophenyl carbonate
• 英文别名: Poly(oxy-1,2-ethanediyl), I+/--[(4-nitrophenoxy)carbonyl]-I-hydroxy-；2-hydroxyethyl (4-nitrophenyl) carbonate
• CAS: 252337-28-3
• 化学式: C₉H₉NO₆
• 分子量: 227.174
• InChiKey: YPODXXZIAFEQNO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  对硝基苯基氯甲酸酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 2-hydroxyethyl 4-nitrophenyl carbonate
  参考文献：
  名称：

  Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them

  摘要：

  式(I)的化合物，或其药学上可接受的盐，或其体内可水解的酯， 其中，例如，X为—O—或—S—； HET是一个可选择的取代的C-连接的含有2到4个异原子（独立选择自N、O和S）的5元杂芳环； Q从Q1和Q2中选择 R2和R3独立地为氢或氟； T从一系列基团中选择，例如，一个N-连接的（完全不饱和的）5元杂芳环系统或式(TC5)的基团： 其中Rc是，例如，R13CO—，R13SO2—或R13CS—； 其中R13是，例如，可选择的取代的(1-10C)烷基或R14C(O)O(1-6C)烷基 其中R14是可选择的取代的(1-10C)烷基；这些化合物可用作抗菌剂；并描述了其制备方法和含有它们的药物组合物。

  公开号：

  US20030144263A1

文献信息

• Releasable polymeric conjugates based on aliphatic biodegradable linkers
  申请人：——

  公开号：US20040037802A1

  公开（公告）日：2004-02-26

  Activated polymeric bicine derivatives such as 1 as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed.

  本发明揭示了活性聚合物bicine衍生物，例如1，以及制备这些衍生物的共轭物。本发明还揭示了制备和使用这些bicine衍生物的方法。
• POLYOXYALKYLENE DERIVATIVE
  申请人：NOF CORPORATION

  公开号：EP1857462A1

  公开（公告）日：2007-11-21

  A novel polyoxyalkylene derivative represented by the following formula (1), wherein each symbol is as defined in the specification, which has a functional group capable of reacting with various physiologically active substances according to the object is provided.

  本发明提供了一种由下式（1）表示的新型聚氧亚烷基衍生物，其中各符号如说明书中所定义，该衍生物具有能与各种生理活性物质发生反应的官能团。
• Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
  申请人：Halozyme, Inc.

  公开号：EP2662090A1

  公开（公告）日：2013-11-13

  Provided are combinations, compositions and kits containing a hyaluronan degrading enzyme, such as a soluble hyaluronidase, for treatment of hyaluronan-associated conditions, diseases and disorders. In one example, the products include an additional agent or treatment. Such products can be used in methods for administering the products to treat the hyaluronan-associated diseases and conditions, for example, hyaluronan-associated cancers, for example, hyaluronan-rich tumors. The methods include administration of the hyaluronan degrading enzyme composition alone or in combination with other treatments. Also provided are methods and compositions for providing sustained treatment effects in hyaluronan-associated diseases and conditions.

  本发明提供了含有透明质酸降解酶（如可溶性透明质酸酶）的组合物、组合物和试剂盒，用于治疗透明质酸相关病症、疾病和失调。在一个例子中，产品包括一种额外的制剂或治疗方法。这类产品可用于给药方法中，以治疗透明质酸相关疾病和病症，例如透明质酸相关癌症，例如富含透明质酸的肿瘤。这些方法包括单独施用透明质酸降解酶组合物或与其他治疗方法联合施用。还提供了对透明质酸相关疾病和病症提供持续治疗效果的方法和组合物。
• MODIFIED HYALURONIDASES FOR USE IN TREATING HYALURONAN-ASSOCIATED DISEASES AND CONDITIONS
  申请人：Halozyme, Inc.

  公开号：EP3192525A1

  公开（公告）日：2017-07-19

  Provided are combinations, compositions and kits containing a hyaluronan degrading enzyme, such as a soluble hyaluronidase, for treatment of hyaluronan-associated conditions, diseases and disorders. In one example, the products include an additional agent or treatment. Such products can be used in methods for administering the products to treat the hyaluronan-associated diseases and conditions, for example, hyaluronan-associated cancers, for example, hyaluronan-rich tumors. The methods include administration of the hyaluronan degrading enzyme composition alone or in combination with other treatments. Also provided are methods and compositions for providing sustained treatment effects in hyaluronan-associated diseases and conditions.

  本发明提供了含有透明质酸降解酶（如可溶性透明质酸酶）的组合物、组合物和试剂盒，用于治疗透明质酸相关病症、疾病和失调。在一个例子中，产品包括一种额外的制剂或治疗方法。这类产品可用于给药方法中，以治疗透明质酸相关疾病和病症，例如透明质酸相关癌症，例如富含透明质酸的肿瘤。这些方法包括单独施用透明质酸降解酶组合物或与其他治疗方法联合施用。还提供了对透明质酸相关疾病和病症提供持续治疗效果的方法和组合物。
• Combination therapy with an anti-hyaluronan agent and therapeutic agent
  申请人：Halozyme, Inc.

  公开号：US10137104B2

  公开（公告）日：2018-11-27

  Provided herein is combination cancer therapy effected by administering a polymer-conjugated hyaluronidase, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.

  本文提供的癌症联合疗法是通过施用聚合物结合的透明质酸酶和肿瘤靶向的紫杉类药物，以及可选的另一种化疗药物，如核苷类似物来实现的。该组合疗法可用于治疗癌症，尤其是实体瘤癌症。